Prosorba column: Received conditional FDA approval to begin a pivotal trial, expected to start in the first quarter of 1996, to enroll up to 268 patients.

Half the patients will receive treatment of their blood through the column, and half will receive sham treatment, once weekly for 12 weeks with three-month follow-up. The conditional approval was gran...